Overview

* Mirum Q2 2025 revenue grows to $128 mln, driven by Livmarli sales

* Company raises 2025 revenue guidance to $490-$510 mln

* Mirum reports Q2 net loss of $5.9 mln despite revenue growth

Outlook

* Mirum raises 2025 revenue guidance to $490-$510 mln

* Company expects Volixibat VISTAS study topline data in Q2 2026

* Mirum plans Phase 2 MRM-3379 study in Fragile X Syndrome in Q4 2025

Result Drivers

* LIVMARLI SALES - Livmarli net product sales reached $88.2 mln, marking an 87% growth over Q2 2024

* INTERNATIONAL SUCCESS - Strong performance from international business and U.S. PFIC launch contributed to revenue growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $127.78

Product mln

Sales

Q2 Net -$5.86

Income mln

Q2 Basic -$0.12

EPS

Q2 $132.77

Operatin mln

g

Expenses

Q2 -$4.99

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Mirum Pharmaceuticals Inc ( MIRM ) is $73.00, about 29% above its August 5 closing price of $51.84

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)